Showing results (1311-1320 of 1,523) with videos related to
Sort By:
Pageof 153
Lancet (London, England)|September 22, 2009
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyTudor Ciuleanu, Thomas Brodowicz, Christoph Zielinski, et al.Iscience|October 9, 2023
Spatial downregulation of CD74 signatures may drive invasive component development in part-solid lung adenocarcinomaJia-Tao Zhang, Juan Zhang, Song-Rong Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2018
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung CancerYi-Long Wu, Li Zhang, Dong-Wan Kim, et al.Journal of Hematology & Oncology|December 7, 2025
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapyYi-Long Wu, Lin Wu, Nan Bi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2018
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR MutationShan Su, Zhong-Yi Dong, Zhi Xie, et al.The New England Journal of Medicine|December 14, 2016
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung CancerTony S Mok, Yi-Long Wu, Myung-Ju Ahn, et al.ACS Applied Materials & Interfaces|April 14, 2022
Enhanced Performance of ΔTad upon Frequent Alternating Magnetic Fields in FeRh Alloys by Introducing Second PhasesKaiming Qiao, Jianlin Wang, Shulan Zuo, et al.Nature Communications|July 21, 2024
ER calcium depletion as a key driver for impaired ER-to-mitochondria calcium transfer and mitochondrial dysfunction in Wolfram syndromeMailis Liiv, Annika Vaarmann, Dzhamilja Safiulina, et al.The Lancet. Respiratory Medicine|December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, et al.Pageof 153